VONVENDI now has a surgical indication

NOW

PREPPED AND

READY FOR SURGERY

VONVENDI®
[von Willebrand factor (Recombinant)]
IS NOW APPROVED FOR PERIOPERATIVE MANAGEMENT OF BLEEDING IN ADULT PATIENTS (AGE 18 AND OLDER).4

Read the press release Surgical Dosing Information

Sign up for more information

Find a Shire rep near you

VONVENDI allows healthcare providers to dose rVWF with or without recombinant factor VIII (rFVIII) based on each patient's individual requirements.4

Learn more about
recombinant therapy
 
GET MORE INFORMATION ON VONVENDI AND OUR LATEST UPDATES
Please enter your Date of birth. Please enter the person with VWD's Date of birth.

For more information please see our privacy statement

By clicking Sign Up, you certify that you are at least 18 years old and you are opting to receive information about von Willebrand disease, Shire von Willebrand disease products, and other information from Shire. You may unsubscribe from these communications at any time by clicking on the unsubscribe link in the email communication.

By providing your personal and/or medical data and clicking on the sign up button, you authorize Shire to contact you about von Willebrand disease, VONVENDI, and other information from Shire. Shire respects your personal information. All personal and/or medical information you have provided will be kept confidential and will not be used or distributed to anyone for any purpose other than what is explained in our Privacy Notice. We encourage you to read our Privacy Notice by clicking on this link: Review Shire Privacy Notice. This consent will be in effect until such time as you opt out of the program.